- Home
- MDGL vs LPX Comparison
MDGL vs LPX Comparison
Compare MDGL & LPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | LPX |
|---|---|---|
| Founded | 2011 | 1973 |
| Country | United States | United States |
| Employees | N/A | 4300 |
| Industry | Biotechnology: Pharmaceutical Preparations | Forest Products |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 4.6B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MDGL | LPX |
|---|---|---|
| Price | $517.04 | $66.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $674.45 | $105.29 |
| AVG Volume (30 Days) | 184.3K | ★ 998.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | $180,133,000.00 | ★ $2,708,000,000.00 |
| Revenue This Year | $58.39 | N/A |
| Revenue Next Year | $48.55 | $11.23 |
| P/E Ratio | ★ N/A | $87.86 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $393.61 | $64.49 |
| 52 Week High | $615.00 | $100.34 |
Technical Indicators
Market Signals| Indicator | MDGL | LPX |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 41.72 |
| Support Level | $501.27 | $65.76 |
| Resistance Level | $546.29 | $76.95 |
| Average True Range (ATR) | 17.15 | 1.98 |
| MACD | -2.23 | 0.25 |
| Stochastic Oscillator | 39.30 | 35.07 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About LPX Louisiana-Pacific Corporation
Louisiana-Pacific Corp is an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The Siding business of the company serves different markets with a broad product portfolio of engineered wood siding, trim, soffit, and fascia. The Company operates through three operating segments: Siding, OSB, and LP South America (LPSA). The company generates majority of its revenue from siding segment.